Join Growin Stock Community!

中天4128.TW Overview

TW StockBiotech. & Medical
(No presentation for 4128)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

中天（4128）Overall Performance

中天（4128）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

中天（4128） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

中天（4128）Key Information

中天（4128）Profile

Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and dietary supplements in Taiwan. The company provides MS-20 for ameliorating fatigue and appetite loss associated with cancer chemotherapy; and Herbiron, which reveals symptoms of iron deficiency anemia and menstrual discomfort. Its pre-clinical stage products include SNA-03 and SNA-07 for cancer immune therapy; SNP-630 to treat non-alcoholic steatohepatitis; FB918 for the treatment of non-allergic eosinophilic asthma; and SNS812 for Cov-flu. The company's Phase I clinical trial products consist of OB-318, an anti-cancer drug; MB-110 for the treatment of hepatitis C; SNP-810, an acetaminophen; FB317 to treat moderate-to-severe allergic asthma and chronic idiopathic urticaria; and FB704A for the treatment of rheumatoid arthritis, cancer, cytokine storms, etc. It also offers FB825, which is in Phase II clinical trial for the treatment of atopic dermatitis, allergic asthma, hyper IgE syndrome, and food allergy. In addition, the company's Phase III clinical trial products comprise ON101 to treat diabetic foot ulcer; and MB-6 that acts as an adjuvant for metastatic colorectal cancer. Further, its discovery stage pipeline includes FB121 for AIDS; SNA01 to treat PD-1 related cancer; SNA02 for cancer immune therapy; and SNS01 for recurrent metastatic non-small cell lung cancer. Additionally, the company develops SNP-830 and SNP-840, a hepatotoxicity-free analgesic. It is also involved in the trading of organic foods; sale of beverages; provision of technology development, transfer, and consultation services; and publishing of magazine, as well as offers business consulting services. Microbio Co., Ltd. was founded in 2000 and is based in Taipei, Taiwan.

中天（4128）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
39.16%
Net Margin
-55.53%
Revenue Growth (YoY)
10.76%
Profit Growth (YoY)
12.21%
3-Year Revenue Growth
-0.66%
3-Year Profit Growth
-3.77%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
39.16%
Net Margin
-55.53%
Revenue Growth (YoY)
10.76%
Profit Growth (YoY)
12.21%
3-Year Revenue Growth
-0.66%
3-Year Profit Growth
-3.77%
default symbol

4128

中天

17.90D

-1.68%

(-0.02)

  • When is 4128's latest earnings report released?

    The most recent financial report for 中天 (4128) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 4128's short-term business performance and financial health. For the latest updates on 4128's earnings releases, visit this page regularly.

  • What is the operating profit of 4128?

    According to the latest financial report, 中天 (4128) reported an Operating Profit of -102.63M with an Operating Margin of -21.66% this period, representing a growth of 7.46% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 4128's revenue growth?

    In the latest financial report, 中天 (4128) announced revenue of 473.78M, with a Year-Over-Year growth rate of 10.6%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 4128 have?

    At the end of the period, 中天 (4128) held Total Cash and Cash Equivalents of 794.88M, accounting for 0.06 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 4128 go with three margins increasing?

    In the latest report, 中天 (4128) did not achieve the “three margins increasing” benchmark, with a gross margin of 38.87%%, operating margin of -21.66%%, and net margin of -27.66%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 4128's profit trajectory and future growth potential.

  • Is 4128's EPS continuing to grow?

    According to the past four quarterly reports, 中天 (4128)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.15. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 4128?

    中天 (4128)'s Free Cash Flow (FCF) for the period is -49.59M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 94.66% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.